Literature DB >> 21558078

Convection-enhanced delivery of a transforming growth factor-beta2 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined?, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).

Marc C Chamberlain.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21558078      PMCID: PMC3093343          DOI: 10.1093/neuonc/nor048

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  3 in total

1.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.

Authors:  E T Wong; K R Hess; M J Gleason; K A Jaeckle; A P Kyritsis; M D Prados; V A Levin; W K Yung
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

2.  Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.

Authors:  Kathleen R Lamborn; W K Alfred Yung; Susan M Chang; Patrick Y Wen; Timothy F Cloughesy; Lisa M DeAngelis; H Ian Robins; Frank S Lieberman; Howard A Fine; Karen L Fink; Larry Junck; Lauren Abrey; Mark R Gilbert; Minesh Mehta; John G Kuhn; Kenneth D Aldape; Janelle Hibberts; Pamela M Peterson; Michael D Prados
Journal:  Neuro Oncol       Date:  2008-03-04       Impact factor: 12.300

3.  Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.

Authors:  U Bogdahn; P Hau; G Stockhammer; N K Venkataramana; A K Mahapatra; A Suri; A Balasubramaniam; S Nair; V Oliushine; V Parfenov; I Poverennova; M Zaaroor; P Jachimczak; S Ludwig; S Schmaus; H Heinrichs; K-H Schlingensiepen
Journal:  Neuro Oncol       Date:  2010-10-27       Impact factor: 12.300

  3 in total
  4 in total

1.  Heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial.

Authors:  Orin Bloch; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2014-04-10       Impact factor: 12.300

Review 2.  Targeting TGF-β Signaling for Therapeutic Gain.

Authors:  Rosemary J Akhurst
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-10-03       Impact factor: 10.005

Review 3.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

4.  The future of high-grade glioma: Where we are and where are we going.

Authors:  Emilie Le Rhun; Emilie Le Rhun; Sophie Taillibert; Marc C Chamberlain
Journal:  Surg Neurol Int       Date:  2015-02-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.